C3.ai, Inc. ("C3 AI," "C3," or the "Company") (NYSE: AI), the Enterprise AI application software company, today announced ...

The CEO is resigning for health reasons. C3.ai's stock has struggled since going public in late 2020 and is down over 75%. C3 ...

Benzinga's options scanner has just identified more than 8 option transactions on C3.ai AI -1.52% Get Free Report , with a cumulative value of $239,958. Concurrently, our algorithms picked up 3 puts, ...

C3.ai, Inc. AI closed fiscal 2025 with strong momentum, positioning its Generative AI and agentic AI platforms as central ...

Shareholders of C3.ai would probably like to forget the past six months even happened. The stock dropped 30.6% and now trades at $23.25. This may have investors wondering how to approach the situation ...

Figma CEO Dylan Field knows people are going to stare at his stock price. “You can’t tell people, ‘Don‘t look at the elephant ...

HII (HII), America’s largest military shipbuilder, and C3 AI (NYSE: AI), the Enterprise AI application software company, have recently announced a strategic partnership to expand digital technologies ...

A new study finds early humans ate tough grasses and tubers long before their teeth adapted, suggesting behavior, not biology, drove human evolution.

The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.